Based on our findings that both p-eIF2A and ATF4 levels were increased upon USP22 loss, together with an enrichment of a PERK-mediated UPR gene expression signature in both in vivo and in vitro models, we postulated that USP22 might suppress PERK activation to maintain low UPR levels in cancer cells. Here, ATF4 is linked to cancer.